<DOC>
	<DOC>NCT00419094</DOC>
	<brief_summary>The primary objective of this study is to assess the efficacy of two doses of Keppra XR compared with a historical control as the placebo, in the monotherapy treatment of partial onset seizures.</brief_summary>
	<brief_title>Conversion to Monotherapy Study With Keppra XR for Partial Seizures</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Male or female subjects 12 to 75 years of age. Subjects must have inadequately controlled partial onset epilepsy. Subjects must be experiencing 2 to 40 seizures per 4week period while being maintained on one or two standard AED(s) A history of status epilepticus in the 6 months preceding randomization. Significant medical, psychiatric or neurological illness. Intake of benzodiazepines on more than an occasional basis History of previous treatment with levetiracetam or sensitivity to levetiracetam.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Keppra XR</keyword>
	<keyword>conversion to monotherapy</keyword>
	<keyword>partial seizures</keyword>
</DOC>